JP7792336B2 - 乳がん治療剤 - Google Patents

乳がん治療剤

Info

Publication number
JP7792336B2
JP7792336B2 JP2022539547A JP2022539547A JP7792336B2 JP 7792336 B2 JP7792336 B2 JP 7792336B2 JP 2022539547 A JP2022539547 A JP 2022539547A JP 2022539547 A JP2022539547 A JP 2022539547A JP 7792336 B2 JP7792336 B2 JP 7792336B2
Authority
JP
Japan
Prior art keywords
breast cancer
fulvestrant
elacestrant
therapeutic agent
pharmacologically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022539547A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022025150A1 (https=
Inventor
智 河野
沙里 宮野
恭子 西端
沙世 福島
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JPWO2022025150A1 publication Critical patent/JPWO2022025150A1/ja
Application granted granted Critical
Publication of JP7792336B2 publication Critical patent/JP7792336B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
JP2022539547A 2020-07-31 2021-07-29 乳がん治療剤 Active JP7792336B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2020130935 2020-07-31
JP2020130935 2020-07-31
JP2020163258 2020-09-29
JP2020163258 2020-09-29
PCT/JP2021/028008 WO2022025150A1 (ja) 2020-07-31 2021-07-29 乳がん治療剤

Publications (2)

Publication Number Publication Date
JPWO2022025150A1 JPWO2022025150A1 (https=) 2022-02-03
JP7792336B2 true JP7792336B2 (ja) 2025-12-25

Family

ID=80035757

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022539547A Active JP7792336B2 (ja) 2020-07-31 2021-07-29 乳がん治療剤

Country Status (11)

Country Link
US (1) US20230172924A1 (https=)
EP (1) EP4151212A4 (https=)
JP (1) JP7792336B2 (https=)
KR (1) KR20230047056A (https=)
CN (1) CN115996722A (https=)
AU (1) AU2021315234A1 (https=)
BR (1) BR112022027069A2 (https=)
CA (1) CA3185174A1 (https=)
MX (1) MX2023000060A (https=)
TW (1) TW202220652A (https=)
WO (1) WO2022025150A1 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015505562A (ja) 2012-01-31 2015-02-23 ノバルティス アーゲー Ｒｔｋ阻害剤と抗エストロゲン剤との組合せ、およびがん治療のためのその使用
WO2017104739A1 (ja) 2015-12-17 2017-06-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 乳がん治療剤
WO2021210636A1 (ja) 2020-04-17 2021-10-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 乳がん治療剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR094812A1 (es) * 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
JP2014235614A (ja) 2013-06-03 2014-12-15 株式会社ゼネット 総合学習支援ネットワークシステム及び総合学習支援方法
KR102344105B1 (ko) 2014-08-18 2021-12-29 에자이 알앤드디 매니지먼트 가부시키가이샤 모노시클릭 피리딘 유도체의 염 및 이의 결정
EP3275442B1 (en) 2015-03-25 2021-07-28 National Cancer Center Therapeutic agent for bile duct cancer
JP2017217935A (ja) 2016-06-03 2017-12-14 株式会社東海理化電機製作所 ステアリングスイッチ装置
JP2018022750A (ja) 2016-08-02 2018-02-08 太陽誘電株式会社 積層セラミックコンデンサ
US11219619B2 (en) * 2018-03-28 2022-01-11 Eisai R&D Management Co., Ltd. Therapeutic agent for hepatocellular carcinoma

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015505562A (ja) 2012-01-31 2015-02-23 ノバルティス アーゲー Ｒｔｋ阻害剤と抗エストロゲン剤との組合せ、およびがん治療のためのその使用
WO2017104739A1 (ja) 2015-12-17 2017-06-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 乳がん治療剤
WO2021210636A1 (ja) 2020-04-17 2021-10-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 乳がん治療剤

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Breast Cancer Research，2017年，Vol.19，pp.1-14
Breast Cancer Research，2019年，Vol.21，pp.1-14
Clinical Cancer Research，2017年，Vol.23, No.20，pp.6138-6150
Molecular Cancer Therapeutics，2016年，Vol.15, No.11，pp.2630-2639
Nature Reviews Clinical Oncology，2019年，Vol. 16, No. 2，pp. 105-122, Supplementary Information
SECKL, Michael et al.，RADICAL trial: A phase Ib/IIa study to assess the safety and efficacy of AZD4547 in combination with either anastrozole or letrozole in ER positive breast cancer patients progressing on these aromatase inhibitoes (AIs).，Journal of Clinical Oncology，Vol.35, No.15, Supplement 1，2017年， (Abstract) EMBASE [online], [retrieved on 2021.08.23], Retrieved from: STN, AN 0052652985

Also Published As

Publication number Publication date
TW202220652A (zh) 2022-06-01
US20230172924A1 (en) 2023-06-08
BR112022027069A2 (pt) 2023-02-07
JPWO2022025150A1 (https=) 2022-02-03
AU2021315234A1 (en) 2023-01-19
MX2023000060A (es) 2023-02-01
CA3185174A1 (en) 2022-02-03
EP4151212A1 (en) 2023-03-22
KR20230047056A (ko) 2023-04-06
EP4151212A4 (en) 2024-04-10
WO2022025150A1 (ja) 2022-02-03
CN115996722A (zh) 2023-04-21

Similar Documents

Publication Publication Date Title
JP7745708B2 (ja) 癌を治療するための方法
EP2783686B1 (en) Combination of a rapamycin derivative and letrozole for treating breast cancer
RU2680714C2 (ru) Комбинированная терапия для лечения рака
US20230149381A1 (en) Breast cancer therapeutic agent
CA3233554A1 (en) Combination therapy using a ptpn11 inhibitor and a kras g12c inhibitor
CN113194946A (zh) 用于治疗血管性埃勒斯-当洛斯综合征和有关障碍的组合物和方法
US20230000876A1 (en) Treating cancers with a cyclin-dependent kinase inhibitor
JP7792336B2 (ja) 乳がん治療剤
UA115447C2 (uk) N-[4-(хінолін-4-ілокси)циклогексил(метил)](гетеро)арилкарбоксаміди як антагоністи андрогенного рецептора, їх одержання і застосування як лікарських засобів
KR20030016222A (ko) 수술후 스트레스 예방ㆍ치료제
JP6748704B2 (ja) 抗癌治療剤
JPWO2004035089A1 (ja) ホルモン依存性癌の治療剤
RU2847580C1 (ru) Терапевтическое средство против рака молочной железы
KR102347516B1 (ko) Ｐａｒｐ 저해용 화합물 및 이의 의약 용도
EP4706656A1 (en) Combination therapy of dacomitinib and nintedanib for prevention or treatment of pulmonary fibrosis
WO2025167971A1 (zh) Pkmyt1抑制剂的药物组合及其用途
CN104684896B (zh) 作为雄激素受体拮抗剂的n‑[4‑(喹啉‑4‑基氧基)环己基(甲基)](杂)芳基甲酰胺、其制法及其用作药品的用途
WO2023178255A9 (en) Combinations comprising metap2 inhibitors for the treatment of cancer
HK40050331A (zh) 用於治疗血管性埃勒斯-当洛斯综合征和有关障碍的组合物和方法
WO2009138779A1 (en) Combination comprising 4- (3-chloro-2-fluoroanilino) -7-meth0xy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxyjquinazoline
WO2009024820A2 (en) Therapeutic treatment 014
HK1198946B (en) Combination of a rapamycin derivative and letrozole for treating breast cancer
HK1146247B (en) Treatment of breast tumors with a rapamycin derivative in combination with exemestane
WO2009110416A1 (ja) 併用剤
HK1206346B (en) N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250617

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251014

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251209

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251215

R150 Certificate of patent or registration of utility model

Ref document number: 7792336

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150